secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0000950170-24-081942
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Therapeutics appoints Tim Van Hauwermeiren, argenx CEO, to Board
----------------------------------------------------------------------

- Appointment effective July 5, 2024; term expires at 2027 annual meeting.
- Standard director comp: $40k annual cash, initial option for 36,000 shares, annual option for 18,000 shares.
- Van Hauwermeiren is co-founder and CEO of argenx; built company to ~$25B market cap.
- No arrangements or family relationships with Lexeo officers; standard indemnification agreement.
- Appointed as independent, non-executive director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/0000950170-24-081942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024081942/lxeo-20240708.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-081942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer